Simulations Plus, Inc. (NASDAQ:SLP) has shared an article detailing how researchers used its DILIsym software platform to understand why patients receiving treatment with valproate (VPA) are more sensitive to liver chemistries due to cannabidiol (CBD). The software predicted dose-dependent ALT elevations for CBD treatment and ALT elevations for VPA treatment when each was given alone, but the combined VPA and CBD treatment did not increase the incidence of ALT elevations relative to CBD treatment on its own.